An experimental drug known as talazoparib has shown promising results in improving survival for women with BRCA1 and BRCA2 genetic mutations. The phase 3 trial, conducted on 431 women at the University of Texas M.D. Anderson Cancer Center, has shown that women receiving talazoparib live longer by about 3 months compared to standard chemotherapy. While the response rate to treatment was promising in the trial conducted, the results are considered preliminary and have not been approved by the U.S. Food and Drug Administration (FDA).
To read more about this trial, click here.
No comments:
Post a Comment